Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319092 | 0.88 | ESR1 (0.56) | KMT2AMEN1GAAESR1ESR2 | |
| SCHEMBL2320102 | 0.87 | PTGS2 (0.53) | KMT2AMEN1GAAESR1ESR2 | |
| SCHEMBL2319344 | 0.85 | GPBAR1 (0.51) | ESR1ESR2PTGS2FFAR4 | |
| SCHEMBL2320097 | 0.85 | GPBAR1 (0.47) | KMT2AMEN1GAAESR1ESR2 | |
| SCHEMBL2318265 | 0.81 | ESR1 (0.50) | KMT2AMEN1GAAESR1ESR2 | |
| SCHEMBL1225880 | 0.81 | POLB (0.56) | GAAPTGS1NPC1GABRA5POLB | |
| SCHEMBL1574735 | 0.78 | KMT2A (0.73) | KMT2AMEN1GAAPOLBALOX15 | |
| SCHEMBL2926411 | 0.76 | PTGS2 (0.51) | ESR1ESR2PTGS2GABRA5FFAR4 | |
| SCHEMBL20507190 | 0.75 | GPBAR1 (0.49) | ESR1ESR2PTGS2FFAR4 | |
| SCHEMBL20507128 | 0.75 | FFAR4 (0.48) | KMT2AMEN1ESR1ESR2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170873-B1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| US-7851469-B2 | Isoxazole-imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-2170873-A1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-04-07 | — | — | EP | disclosed |
| US-20090005370-A1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-01-01 | — | — | US | disclosed |
| WO-2009000662-A1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005370-A1 | ISOXAZOLE-IMIDAZOLE DERIVATIVES | GABRA5, GABRA1, GABRA4 | KMT2A 2713/4885MEN1 4422/4885GAA 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.